复发性或转移性宫颈癌患者的真实世界治疗中断:基于美国社区肿瘤学的分析
本研究为回顾性观察性队列研究,纳入2014年9月1日至2019年12月31日期间接受一线治疗的262例复发性或转移性宫颈癌成年女性,随访至2020年12月31日。结果显示,48%完成一线治疗的患者接受了二线治疗,一线治疗开始至治疗停止的中位时间为3.5个月,一线治疗停止后中位无治疗间期为2.1个月。作者结论认为超过50%的一线治疗患者未接受二线治疗,凸显对新有效治疗方案的需求。
要点
- 262例患者中66%一线接受铂类双药化疗联合贝伐珠单抗,24%接受双药化疗 alone。
- 完成一线治疗的患者中48%接受二线治疗,二线无一致首选方案。
- 一线治疗开始至治疗停止中位时间3.5个月,停止后中位无治疗间期2.1个月。
核心结论
- 超过50%启动一线治疗的患者未接受二线治疗,凸显对新有效治疗方案的需求。
- 随着治疗格局演变,作者预期更多患者将因多线治疗选择而生存更久。
研究设计与样本
- 回顾性观察性队列研究,使用美国肿瘤网络电子健康记录和病历回顾数据,纳入2014年9月1日至2019年12月31日接受一线治疗的复发性或转移性宫颈癌成年女性,随访至2020年12月31日,共262例符合标准(平均年龄53岁)。
主要发现
- 一线治疗中66%接受铂类化疗双药联合贝伐珠单抗,24%接受化疗双药 alone。
- 完成一线治疗的患者中48%接受二线治疗,二线无一致首选方案。
- 一线治疗开始至治疗停止的中位时间为3.5个月,一线治疗停止后中位无治疗间期为2.1个月。
- 除血清肌酐升高外,体重指数异常显示接受二线治疗可能性降低的方向性趋势;其他预测因素可能包括既往未使用贝伐珠单抗、ECOG评分较差和较早的疾病预防。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Understanding real-world treatment patterns and proportions of eligible patients in each line of treatment is imperative to inform future clinical trial designs and multi-line treatment algorithm development. METHODS: We conducted a retrospective observational cohort study of adult women who received first-line (1 L) therapy for r/mCC between 01 September 2014 and 31 December 2019, using The US Oncology Network electronic health records and chart review data. Patients were followed to 31 December 2020. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. RESULTS: A total of 262 patients with r/mCC met study inclusion criteria (mean age = 53 years). The majority of patients in 1 L received platinum-based chemotherapy doublet plus bevacizumab (66%) or chemotherapy doublet alone (24%). Nearly half the patients (48%) completing 1 L received 2 L therapy. Among these patients, there was no consistent 2 L treatment of choice. Overall median time to treatment discontinuation was 3.5 months from 1 L treatment initiation, and median overall treatment-free interval was 2.1 months from 1 L discontinuation. Besides elevated serum creatinine, abnormal BMI indicated a directional trend for lower likelihood of receiving 2 L. Other predictors may include no prior bevacizumab, worse ECOG, and earlier disease prevention. CONCLUSIONS: >50% of the patients who initiated 1 L treatment did not receive 2 L therapy, highlighting the need for novel and effective treatment options. As the treatment landscape continues to evolve, we anticipate that more patients will live longer with more treatment options across multiple lines of therapies in the r/mCC setting.
引用
- Alholm Z, He D, Ting J, et al. Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis. Gynecol Oncol. 2022. PMID: 35914979. doi:10.1016/j.ygyno.2022.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。